At the same time, clinical studies have found that the serum S100A8/A9 level is closely related to the severity of atherosclerosis and the risk of cardiovascular events, which is expected to become a potential biomarker and therapeutic target of atherosclerosis (46). This evidence concerns the gene S100A8 and atherosclerosis.